TY - JOUR
T1 - Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insnlin requirement of patients on insulin pump therapy
AU - Rabiee, Atoosa
AU - Galiatsatos, Panagis
AU - Salas-Carrillo, Rocio
AU - Thompson, Michael J.
AU - Andersen, Dana K.
AU - Elahi, Dariush
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2011/11
Y1 - 2011/11
N2 - Introduction: The effects of pancreatic polypeptide (PP) infusion were examined in patients on insulin pump therapy to determine whether PP administration can reduce insulin requirements in patients with type 1 diabetes mellitus (T1DM) or type 3c diabetes mellitus (T3cDM; pancreatogenic). Methods: Ten subjects with long-standing T1DM (n = 7) or T3cDM (n = 3) on insulin pump treatment received a 72 h subcutaneous infusion of 2 pmol/kg/min bovine PP or saline by portable infusion pump in a single-blinded, randomized, crossover design. Results: Pancreatic polypeptide infusion raised plasma PP levels to 450-700 pmol/liter. Daily insulin infusion requirements (I) fell from 48 ± 6.9 to 40 ± 7.5 U on day 2 (p < .05) and from 46 ± 7.7 to 37 ± 6.6 U on day 3 (p < .05) of PP infusion compared with saline. Corrected for average blood glucose concentration (G), I/G fell in 10/10 subjects during the second 24 h period and in 7/10 subjects during the third 24 h period; sensitivity to insulin, calculated as 1 /(I/G), increased 45% ± 12% on day 2 (p < .01) and 34% ± 1-4% on day 3 (p < .05) of PP infusion. Pancreatic polypeptide responses to a test meal were compared with the change in insulin infusion requirements in 5 subjects; the reduction in insulin requirements seen during PP infusion correlated with the degree of baseline PP deficiency (p < .002). Conclusions: A concurrent subcutaneous infusion of PP enhances insulin sensitivity and reduces insulin requirements in patients with long-standing T1DM and T3cDM on insulin pump therapy. The benefit of PP infusion correlated with the degree of PP deficiency.
AB - Introduction: The effects of pancreatic polypeptide (PP) infusion were examined in patients on insulin pump therapy to determine whether PP administration can reduce insulin requirements in patients with type 1 diabetes mellitus (T1DM) or type 3c diabetes mellitus (T3cDM; pancreatogenic). Methods: Ten subjects with long-standing T1DM (n = 7) or T3cDM (n = 3) on insulin pump treatment received a 72 h subcutaneous infusion of 2 pmol/kg/min bovine PP or saline by portable infusion pump in a single-blinded, randomized, crossover design. Results: Pancreatic polypeptide infusion raised plasma PP levels to 450-700 pmol/liter. Daily insulin infusion requirements (I) fell from 48 ± 6.9 to 40 ± 7.5 U on day 2 (p < .05) and from 46 ± 7.7 to 37 ± 6.6 U on day 3 (p < .05) of PP infusion compared with saline. Corrected for average blood glucose concentration (G), I/G fell in 10/10 subjects during the second 24 h period and in 7/10 subjects during the third 24 h period; sensitivity to insulin, calculated as 1 /(I/G), increased 45% ± 12% on day 2 (p < .01) and 34% ± 1-4% on day 3 (p < .05) of PP infusion. Pancreatic polypeptide responses to a test meal were compared with the change in insulin infusion requirements in 5 subjects; the reduction in insulin requirements seen during PP infusion correlated with the degree of baseline PP deficiency (p < .002). Conclusions: A concurrent subcutaneous infusion of PP enhances insulin sensitivity and reduces insulin requirements in patients with long-standing T1DM and T3cDM on insulin pump therapy. The benefit of PP infusion correlated with the degree of PP deficiency.
KW - Hepatic insulin sensitivity
KW - Insulin, insulin pump treatment
KW - Pancreatic polypeptide
KW - Type 1 diabetes
KW - Type 3c diabetes
UR - http://www.scopus.com/inward/record.url?scp=84862656393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862656393&partnerID=8YFLogxK
U2 - 10.1177/193229681100500629
DO - 10.1177/193229681100500629
M3 - Article
C2 - 22226275
AN - SCOPUS:84862656393
VL - 5
SP - 1521
EP - 1528
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
SN - 1932-2968
IS - 6
ER -